Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC

被引:10
作者
Chang, John Wen-Cheng [1 ,2 ]
Shih, Chun-Liang [3 ]
Wang, Chih-Liang [2 ,4 ]
Luo, Ji-Dung [3 ,5 ]
Wang, Chih-Wei [6 ]
Hsieh, Jia-Juan [1 ]
Yu, Chia-Jung [3 ,4 ,7 ]
Chiou, Chiuan-Chian [3 ,4 ,8 ,9 ]
机构
[1] Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Taoyuan, Taiwan
[2] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[3] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Taoyuan, Taiwan
[4] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan
[5] Rockefeller Univ, Bioinformat Resource Ctr, 1230 York Ave, New York, NY 10021 USA
[6] Chang Gung Mem Hosp, Dept Anat Pathol, Taoyuan, Taiwan
[7] Chang Gung Univ, Coll Med, Dept Cell & Mol Biol, Taoyuan, Taiwan
[8] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Taoyuan, Taiwan
[9] Chang Gung Univ, Dept Med Biotechnol & Lab Sci, 259 Wenhwa 1st Rd, Taoyuan 333, Taiwan
关键词
PCTK1/CDK16; biomarker; non-small cell lung cancer; circulating mRNA; CELL LUNG-CANCER; PROGNOSTIC BIOMARKER; PROTEIN; SERUM; MICROARRAY; EXPRESSION; BREAST; BRAIN; COLLECTION; MICRORNAS;
D O I
10.21873/cgp.20170
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Circulating mRNA can be a useful source of cancer biomarkers. We took advantage of direct transcriptomic analysis in plasma RNA to identify novel mRNA markers for non-small cell lung cancer (NSCLC). Patients and Methods: Plasma RNA from NSCLC patients and healthy individuals was profiled with cDNA-mediated annealing, selection, extension and ligation (DASL) microarrays. The microarray results were further validated in plasma RNA. Results: Through RNA profiling and online database mining, four gene transcripts were filtered as candidate markers of NSCLC. After validation, the PCTAIRE-1 transcript was identified as a circulating mRNA marker. The diagnostic potential of PCTAIRE-1 was evaluated by receiver operating characteristic curve analysis, which gave a sensitivity and specificity of 60% and 85%, respectively. In addition, high plasma PCTK1 levels were also correlated with poor progression free survival (p=0.008). Conclusion: Circulating mRNA can be profiled with the DASL assay. From the profile, PCTAIRE-1 RNA in the plasma we discovered as a novel diagnostic/prognostic biomarker and an indicator of poor survival in NSCLC patients.
引用
收藏
页码:91 / 100
页数:10
相关论文
共 50 条
  • [31] Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
    Lou, Ning
    Wang, Guibin
    Wang, Yanrong
    Xu, Meng
    Zhou, Yu
    Tan, Qiaoyun
    Zhong, Qiaofeng
    Zhang, Lei
    Zhang, Xiaomei
    Liu, Shuxia
    Luo, Rongrong
    Wang, Shasha
    Tang, Le
    Yao, Jiarui
    Zhang, Zhishang
    Shi, Yuankai
    Yu, Xiaobo
    Han, Xiaohong
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2023, 22 (09)
  • [32] Retrospective Analysis of BRCA1/2 Alterations in Advanced NSCLC Using An Amplicon-based NGS Liquid Biopsy Assay
    Poh, J.
    Kaur, H.
    Pek, M.
    Choudhury, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S576 - S577
  • [33] Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment
    Ntzifa, Aliki
    Marras, Theodoros
    Kallergi, Galatea
    Kotsakis, Athanasios
    Georgoulias, Vasilis
    Lianidou, Evi
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
    Kloten, Vera
    Lampignano, Rita
    Krahn, Thomas
    Schlange, Thomas
    [J]. CELLS, 2019, 8 (08)
  • [35] Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma
    Qian, Yiguan
    Li, Yang
    Chen, Ke
    Liu, Ning
    Hong, Xi
    Wu, Di
    Xu, Zheng
    Zhou, Liuhua
    Xu, Luwei
    Jia, Ruipeng
    Ge, Yu-Zheng
    [J]. JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 1099 - 1116
  • [36] Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients
    Noda, Miwa
    Masuda, Takaaki
    Ito, Shuhei
    Tobo, Taro
    Kitagawa, Akihiro
    Hu, Qingjiang
    Shimizu, Dai
    Eguchi, Hidetoshi
    Etoh, Tsuyoshi
    Ohno, Shinji
    Inomata, Masafumi
    Mimori, Koshi
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (10) : 4035 - 4043
  • [37] PD-L1 Expression as Predictive Biomarker in Patients with NSCLC: A Pooled Analysis
    Passiglia, Francesco
    Bronte, Giuseppe
    Rizzo, Sergio
    Galvano, Antonio
    Sortino, Giovanni
    Musso, Emmanuela
    Listi, Angela
    Barraco, Nadia
    Castiglia, Marta
    Calo, Valentina
    Bazan, Viviana
    Cicero, Giuseppe
    Rolfo, Christian
    Russo, Antonio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S232 - S233
  • [38] A novel circRNA-miRNA-mRNA network identifies circ-YOD1 as a biomarker for coronary artery disease
    Miao, Liu
    Yin, Rui-Xing
    Zhang, Qing-Hui
    Liao, Pei-Juan
    Wang, Yong
    Nie, Rong-Jun
    Li, Hui
    [J]. SCIENTIFIC REPORTS, 2019, 9 (1)
  • [39] A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker
    Huang, Yangqing
    Zhou, Xinlan
    Li, Xiufen
    Huang, Dan
    Fang, Zhong
    Ding, Rongrong
    [J]. ONCOLOGY RESEARCH, 2023, 31 (02) : 193 - 205
  • [40] Exploring Optimal Biomarker Sources: A Comparative Analysis of Exosomes and Whole Plasma in Fasting and Non-Fasting Conditions for Liquid Biopsy Applications
    Nasu, Masaki
    Khadka, Vedbar S.
    Jijiwa, Mayumi
    Kobayashi, Ken
    Deng, Youping
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)